Sutro Biopharma (STRO) Competitors $0.85 +0.01 (+1.35%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$0.85 0.00 (-0.08%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STRO vs. GALT, EDIT, AARD, ACIU, TECX, IMAB, NMRA, SOPH, ABEO, and ALLOShould you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Galectin Therapeutics (GALT), Editas Medicine (EDIT), Aardvark Therapeutics (AARD), AC Immune (ACIU), Tectonic Therapeutic (TECX), I-Mab (IMAB), Neumora Therapeutics (NMRA), SOPHiA GENETICS (SOPH), Abeona Therapeutics (ABEO), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry. Sutro Biopharma vs. Its Competitors Galectin Therapeutics Editas Medicine Aardvark Therapeutics AC Immune Tectonic Therapeutic I-Mab Neumora Therapeutics SOPHiA GENETICS Abeona Therapeutics Allogene Therapeutics Sutro Biopharma (NASDAQ:STRO) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk. Which has more volatility and risk, STRO or GALT? Sutro Biopharma has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Does the media favor STRO or GALT? In the previous week, Galectin Therapeutics had 3 more articles in the media than Sutro Biopharma. MarketBeat recorded 5 mentions for Galectin Therapeutics and 2 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.08 beat Galectin Therapeutics' score of 0.00 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is STRO or GALT more profitable? Galectin Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -201.32%. Galectin Therapeutics' return on equity of 0.00% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Sutro Biopharma-201.32% -852.70% -58.67% Galectin Therapeutics N/A N/A -225.32% Do analysts recommend STRO or GALT? Sutro Biopharma presently has a consensus target price of $4.47, indicating a potential upside of 423.21%. Galectin Therapeutics has a consensus target price of $6.00, indicating a potential upside of 26.58%. Given Sutro Biopharma's higher probable upside, equities research analysts plainly believe Sutro Biopharma is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sutro Biopharma 2 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Galectin Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals believe in STRO or GALT? 97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 3.6% of Sutro Biopharma shares are held by insiders. Comparatively, 50.1% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable valuation and earnings, STRO or GALT? Galectin Therapeutics has lower revenue, but higher earnings than Sutro Biopharma. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSutro Biopharma$62.04M1.17-$227.46M-$2.53-0.34Galectin TherapeuticsN/AN/A-$47.05M-$0.64-7.41 SummarySutro Biopharma beats Galectin Therapeutics on 8 of the 14 factors compared between the two stocks. Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STRO vs. The Competition Export to ExcelMetricSutro BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.40M$3.35B$6.10B$10.55BDividend YieldN/A2.28%5.69%4.75%P/E Ratio-0.3421.5785.6027.60Price / Sales1.17273.73538.21205.12Price / CashN/A47.1237.9261.55Price / Book1.5810.1413.246.76Net Income-$227.46M-$52.31M$3.30B$275.88M7 Day Performance-5.39%5.14%4.35%2.81%1 Month Performance-12.05%14.68%9.51%9.24%1 Year Performance-75.33%30.98%88.04%35.42% Sutro Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STROSutro Biopharma4.1094 of 5 stars$0.85+1.4%$4.47+423.2%-75.7%$71.40M$62.04M-0.34240Analyst ForecastGap DownGALTGalectin Therapeutics1.2825 of 5 stars$4.22-7.3%$6.00+42.2%+73.0%$291.47MN/A-6.599Analyst ForecastEDITEditas Medicine4.2496 of 5 stars$3.52+8.6%$5.10+44.9%+30.9%$291.34M$32.31M-1.24230News CoverageAnalyst ForecastAARDAardvark Therapeutics4.4892 of 5 stars$13.68+3.4%$31.17+127.8%N/A$287.05MN/A0.0018Analyst ForecastACIUAC Immune2.1441 of 5 stars$3.04+7.0%$10.00+228.9%+6.3%$285.17M$31.02M-5.24140Positive NewsAnalyst ForecastTECXTectonic Therapeutic2.7949 of 5 stars$15.92+4.7%$80.29+404.3%-51.9%$284.42MN/A-3.94120News CoverageAnalyst ForecastIMABI-Mab2.8595 of 5 stars$3.42-1.7%$7.00+104.7%+272.8%$284.18M$3.89M0.00380Analyst ForecastNMRANeumora Therapeutics2.4165 of 5 stars$1.76+1.1%$7.14+305.8%-86.8%$281.79MN/A-1.12108Analyst ForecastSOPHSOPHiA GENETICS2.1923 of 5 stars$4.43+7.3%$8.00+80.6%+32.2%$279.10M$65.17M-10.07520News CoverageAnalyst ForecastHigh Trading VolumeABEOAbeona Therapeutics4.342 of 5 stars$5.33-2.0%$19.50+265.9%-15.2%$278.95M$3.50M7.6190News CoverageAnalyst ForecastALLOAllogene Therapeutics2.7345 of 5 stars$1.27+1.6%$8.44+564.9%-46.4%$277.35M$20K-1.14310Analyst ForecastGap Up Related Companies and Tools Related Companies Galectin Therapeutics Alternatives Editas Medicine Alternatives Aardvark Therapeutics Alternatives AC Immune Alternatives Tectonic Therapeutic Alternatives I-Mab Alternatives Neumora Therapeutics Alternatives SOPHiA GENETICS Alternatives Abeona Therapeutics Alternatives Allogene Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STRO) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
